Three hormone pathways, one weekly shot. Eli Lilly's investigational triple agonist just posted the largest weight loss of any published phase 3 obesity trial — here's what the TRIUMPH-1 data actually says, and why it isn't in pharmacies yet.
Retatrutide is a once-weekly injectable that activates receptors for three hormones at once: GIP and GLP-1 — the same two targeted by tirzepatide (Mounjaro, Zepbound) — plus glucagon, which tirzepatide doesn't touch. Adding a glucagon effect is meant to push energy expenditure up alongside the appetite suppression the other two pathways already provide.
It is not approved anywhere yet. Eli Lilly has not filed for FDA or EMA approval, and outside estimates put a decision no earlier than 2027. Nothing in this article changes what to do with a current semaglutide or tirzepatide prescription — retatrutide is still a research drug.
TRIUMPH-1 randomized 2,339 adults with obesity or overweight plus at least one weight-related condition, and without diabetes, to once-weekly retatrutide at 4mg, 9mg, or 12mg (each reached through gradual titration from a 2mg starting dose) or placebo, for 80 weeks. Eli Lilly announced topline results on 21 May 2026.
A subset of 532 participants who entered the trial with a BMI of 35 or higher, and who had tolerated their assigned dose, were then escalated to the highest dose they could tolerate (9mg or 12mg) for an additional 24 weeks. By week 104, this group had lost an average of 30.3% of their starting body weight — a reduction historically associated with bariatric surgery, not an injection.
Side effects tracked with dose: at 12mg, 42.4% of participants reported nausea versus 14.8% on placebo, alongside diarrhea (32.0% vs. 13.5%), constipation (26.1% vs. 10.9%), and vomiting (25.3% vs. 4.8%). Discontinuations due to side effects rose with dose too — 4.1% at 4mg, 6.9% at 9mg, 11.3% at 12mg — though the lowest dose actually discontinued less often than placebo (4.9%). For context, the highest tested doses of tirzepatide and semaglutide have each shown roughly 20% weight loss at a comparable ~72-week mark in their own earlier trials.
Sources: Eli Lilly, TRIUMPH-1 topline results announcement, 21 May 2026 (NCT05929066) · The Pharmaceutical Journal coverage · AJMC coverage, including per-dose adverse-event and discontinuation data.
Retatrutide remains investigational, and full results still need to clear peer review before the field treats these numbers as settled. Lilly has said it plans to present detailed TRIUMPH-1 data at the American Diabetes Association's Scientific Sessions and expects further phase 3 readouts — including a trial in type 2 diabetes and one in cardiovascular disease — later this year. A regulatory filing hasn't happened yet, and pharmacist commentary on the announcement pegged approval as unlikely before 2027.
The pattern that matters more than any one drug: every next-generation candidate in this class, retatrutide included, keeps the same once-weekly injection cadence as Ozempic, Wegovy, Mounjaro, and Zepbound. If and when one reaches approval, it slots into the same weekly reminder habit people already have — not a new routine to learn.
This article summarizes a single company-announced phase 3 topline readout and secondary press coverage for general education. Retatrutide is investigational and not yet approved by the FDA or EMA; figures may be revised on peer-reviewed publication. This is not medical advice — talk to your prescriber about your own treatment options.